Showing 5901-5910 of 7140 results for "".
- New Psoriasis Drug Taltz Shows Benefit Through 60 Weekshttps://practicaldermatology.com/news/new-psoriasis-drug-taltz-shows-benefit-through-60-weeks/2458536/Three new studies demonstrate the efficacy and safety of Eli Lilly's Taltz® (ixekizumab) through 60 weeks among patients with moderate-to-severe plaque psoriasis. The findings appear in the
- Derm Salaries On The Risehttps://practicaldermatology.com/news/derm-salaries-on-the-rise/2458537/Starting salaries for dermatologists spiked 13 percent in the last 12 months, according to a new report from Merritt Hawkins. The average annual salary for a dermatologist in 2015-2016 was $444,000, with a low of $250,00 and a high of $650
- Acne Scars: Survey Highlights the Negative Ways Acne and Acne Scars Can Affect Confidencehttps://practicaldermatology.com/news/acne-scars-survey-highlights-the-negative-ways-acne-and-acne-scars-can-affect-quality-of-life/2458539/Ninety-nine percent people would have more confidence if their acne and acne scars were gone, according to a new survey for Suneva Medical. When it comes to skin issues, respondents feel that acne scars are worse than having acne, eczema or rosacea. Nearly half of adults still have
- Kate Bosworth Partners with Allergan for ACZONE® Gel, 7.5% Launchhttps://practicaldermatology.com/news/kate-bosworth-partners-with-allergan-for-aczone-gel-75-launch/2458540/Actress, producer and model Kate Bosworth is the new face of Allergan plc’s ACZONE® (dapsone) Gel, 7.5%. ACZONE® Gel, 7.5% is a once-a-day prescription topical treatment for acne in patients 12 years of age and older. It was approved
- Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Studyhttps://practicaldermatology.com/news/dupilumab-with-topical-corticosteroids-tcs-superior-to-tcs-alone-in-long-term-atopic-dermatitis-study/2458541/Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD CHRONOS study. Reported by Regeneron Pharmaceuticals, Inc. and Sanofi, the phase 3 study involved
- Dermira's DRM04 Shows Promise for Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/dermiras-drm04-shows-promise-for-primary-axillary-hyperhidrosis/2458543/Dermira’s DRM04 may help put the brakes on primary axillary hyperhidrosis, according to topline results from two Phase 3 trials. Based on the results of these trials, Dermira plans to submit a New Drug Application to the US Food and Drug Administ
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti
- Allergan's TEFLARO® OK'd for Pediatric Patientshttps://practicaldermatology.com/news/allergans-teflaro-oked-for-pediatric-patients/2458547/Allergan’s TEFLARO® (ceftaroline fosamil) is now indicated for pediatric patients, making it the first branded IV antibiotic approved for this population in more than a decade. The U.S. Food and Drug Administration (FDA) appr
- New Nair Survey Shows Unwanted Body Hair is No Confidence Boosterhttps://practicaldermatology.com/news/new-nair-survey-shows-unwanted-body-hair-is-no-confidence-booster/2458552/Just shy of 80 percent of women are more confident when they do not have unwanted body hair, according to a recent online survey conducted by Harris Poll on behalf of Church & Dwight Co., Inc., the makers of Nair™. Who Wears Short Shorts? Nair for Short Shorts</
- Novel Topical AD Drug Shows Promise in Phase 2 Studyhttps://practicaldermatology.com/news/novel-ad-drug-shows-promise-in-phase-2-study/2458555/Medimetriks’ MM36 (previously known as OPA-15406) performed well in a Phase 2 trial for the treatment of mild-to-moderate atopic dermatitis, a new study in in Journal of the American Academy of Dermatology shows. The investigational t